Sigyn Therapeutics, Inc.
SIGY
$2.76
-$0.99-26.40%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.00% | 39.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.03% | 14.25% | |||
| Operating Income | 14.03% | -14.25% | |||
| Income Before Tax | -117.05% | -27.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -117.05% | -27.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -117.05% | -27.89% | |||
| EBIT | 14.03% | -14.25% | |||
| EBITDA | 13.81% | -14.29% | |||
| EPS Basic | -117.05% | -26.83% | |||
| Normalized Basic EPS | -114.44% | -18.05% | |||
| EPS Diluted | -115.24% | -26.47% | |||
| Normalized Diluted EPS | -114.44% | -18.05% | |||
| Average Basic Shares Outstanding | 0.00% | 0.84% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||